Lakefront Biotherapeutics (LKFT) Income towards Parent Company (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Income towards Parent Company data on file, last reported at $17.0 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at $17.0 million, up 110.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $928.2 million (up 804.72% YoY), and the FY2025 annual result was $373.5 million, up 371.84% from the prior year.
• Income towards Parent Company declined to $17.0 million in Q1 2026 per LKFT's latest filing, from $910.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $910.5 million in Q4 2025 and troughed at -$211.4 million in Q4 2022.
• A 5-year average of $54.1 million and a median of $3.4 million in 2024 frame the typical range for Income towards Parent Company.
• On a YoY basis, Income towards Parent Company climbed as much as 3266.69% in 2025 and fell as far as 264.64% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$211.4 million in 2022, then jumped by 180.19% to $169.5 million in 2023, then plunged by 84.05% to $27.0 million in 2024, then soared by 3266.69% to $910.5 million in 2025, then slumped by 98.14% to $17.0 million in 2026.
• Business Quant data shows LKFT's Income towards Parent Company at $17.0 million in Q1 2026, $910.5 million in Q4 2025, and $2.2 million in Q3 2025.